Erratum: Early introduction of subcutaneous hepatitis b immunoglobulin following liver transplantation for hepatitis B virus infection: A prospective, multicenter study (Transplantation (2016) 100: 7 (1507-1512) DOI: 10.1097/TP.0000000000001171);Early introduction of subcutaneous hepatitis B immunoglobulin following liver transplantation for hepatitis B virus infection: A prospective, multicenter study

Transplantation

Volumn 100, Issue 7, 2016, Pages 1507-1512

  De Simone, Paolo ^a   Romagnoli, Renato ^b   Tandoi, Francesco ^b   Carrai, Paola ^a   Ercolani, Giorgio ^c   Peri, Eugenia ^c   Zamboni, Fausto ^d   Mameli, Laura ^d   Di Benedetto, Fabrizio ^e   Cillo, Umberto ^f   De Carlis, Luciano ^g   Lauterio, Andrea ^g   Lupo, Luigi ^h   Tisone, Giuseppe ⁱ   Prieto, Martin ^j   Loinaz, Carmelo ^k   Mas, Antoni ^l   Suddle, Abid ^m   Mutimer, David ⁿ   Roche, Bruno ^o,p   Wartenberg Demand, Andrea ^q   Niemann, Gabriele ^q   Böhm, Heike ^q   Samuel, Didier ^o,p   more..

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^c UO Chirurgia dei Trapianti di Fegato e Multiorgano   (Italy)

^d Centro Trapianti di Fegato e Pancreas   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^g OSPEDALE NIGUARDA CA GRANDA   (Italy)

^h DETO Sezione Chirurgia generale e trapianto di fegato Policlinico Consorzile   (Italy)

ⁱ TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l HOSPITAL CLÍNIC   (Spain)

^m KING S COLLEGE HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^o INSERM   (France)

^p UNIVERSITÉ PARIS SACLAY   (France)

^q BIOTEST AG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CORTICOSTEROID; CYCLOSPORIN; ENTECAVIR; EVEROLIMUS; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE; MYCOPHENOLATE MOFETIL; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; RAPAMYCIN; TACROLIMUS; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN;

ADULT; AGED; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; CAREGIVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELF ADMINISTRATION; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HUMAN; INJECTION SITE REACTION; LIVER DISEASE; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; REINFECTION; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; HEPATITIS B VIRUS; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; INJECTIONS, SUBCUTANEOUS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE;

EID: 84961944312     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001726     Document Type: Erratum

References (27)

1. Chen J, Yi L, Jia JD, et al. Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: A systematic review. J Gastroenterol Hepatol. 2010;25:872-879.
2. Cholongitas E, Goulis J, Akriviadis E, et al. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review. Liver Transpl. 2011;17:1176-1190.
3. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329: 1842-1847.
4. Adam R, Karam V, Delvart V, et al. A report from the European Liver Transplant Registry (ELTR). All contributing centers (www. eltr. org); European Liver and Intestine Transplant Association (ELITA). Evolution of indications and results of liver transplantation in Europe. J Hepatol. 2012;57: 675-688.
5. Roche B, Samuel D. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin Liver Dis. 2013;17: 451-473.
6. Katz LH, Paul M, Guy DG, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both Systematic review and meta-analysis. Transpl Infect Dis. 2010;12:292-308.
7. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006;12:253-258.
8. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. Hepatology. 2000;32:1189-1195.
9. Degertekin B, Han SH, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant. 2010;10:1823-1833.
10. Congly SE, Burak KW, Coffin CS. Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. Expert Rev Clin Immunol. 2011;7:429-436.
11. Marzano A, Marengo A, Andreone P, et al. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. Minerva Med. 2010; 101:373-383.
12. Faust D, Rabenau HF, Allwinn R, et al. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant. 2003;17:254-258.
13. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000; 6:429-433.
14. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132:931-937.
15. Kasraianfard A, Watt KD, Lindberg L, et al. HBIG remains significant in the era of new potent nucleoside analogues for prophylaxis against hepatitis B recurrence after liver transplantation. Int Rev Immunol. 2014;6:1563-5244.
16. Thürmann PA, Szymanski J, Haffner S, et al. Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. Eur J Clin Pharmacol. 2006;62:511-512.
17. Singham J, Greanya ED, Lau K, et al. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol. 2010;9:166-171.
18. Yahyazadeh A, BeckebaumS, Cicinnati V, et al. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: An open, prospective, single-arm Phase III study. Transpl Int. 2011;24: 441-450.
19. Di Costanzo GG, Lanza AG, Picciotto FP, et al. Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: An open single-arm prospective study. Am J Transplant. 2013;13: 348-352.
20. Committee for Medicinal Products for Human Use. Guideline on the core SPC for human plasma derived hepatitis-B immunoglobulin for intravenous use (CPMP/BPWG/4027/02). http://www. ema. europa. eu/docs/ en-GB/document-library/Scientific-guideline/2009/09/WC500003325. pdf. Accessed 20th February 2015.
21. LauchartW, Müller R, Pichlmayr R. Long-termimmunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc. 1987;19:4051-4053.
22. Powell JJ, Apiratpracha W, Partovi N, et al. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clin Transplant. 2006;20:524-525.
23. Klein CG, Cicinnati V, Schmidt H, et al. Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: A prospective, observational, multicenter study. Ann Transplant. 2013;18:677-684.
24. De Simone P, Carrai P, Ducci J, et al. Early switching to subcutaneous antihepatitis B virus immunoglobulins (HBIg) after liver transplantation: 6-month results of a single-center study. Liver Transpl. 2012;18(Suppl S1):S222 [Abstract P-262].
25. Ferretti G, Merli M, Ginanni Corradini S, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc. 2004; 36:535-538.
26. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and lowdose hepatitis B immune globulin. Liver Transpl Surg. 1999;5: 520-525.
27. Mas A, Castells L, Abradelo M, et al. Evaluation of Anti-HBs serum levels and pharmacokinetic profile after intravenous administration of Niuliva, a new hepatitis B immunoglobulin, following liver transplantation. Transplant Proc. 2009;41:4253-4258.